Responses
Regular and young investigator award abstracts
Clinical trials in progress
325 Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells
Compose a Response to This Article
Other responses
No responses have been published for this article.
